2024
ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
Arrillaga-Romany I, Gardner S, Odia Y, Aguilera D, Allen J, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit K, Graber J, Haggiagi A, Harrison R, Kheradpour A, Kilburn L, Kurz S, Lu G, MacDonald T, Mehta M, Melemed A, Nghiemphu P, Ramage S, Shonka N, Sumrall A, Tarapore R, Taylor L, Umemura Y, Wen P. ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. Journal Of Clinical Oncology 2024, 42: 1542-1552. PMID: 38335473, PMCID: PMC11095894, DOI: 10.1200/jco.23.01134.Peer-Reviewed Original ResearchConceptsH3 K27M-mutant diffuse midline gliomaDiffuse midline gliomaDuration of responseTime to responseHigh-grade gliomasLow-grade gliomasMidline gliomaMedian duration of responseMedian time to responseTreatment-emergent adverse eventsEnd pointsBlinded independent central reviewCorticosteroid dose reductionIndependent central reviewSecondary end pointsClinically meaningful efficacyRadiographic end pointsSpinal tumorsDose reductionDismal prognosisCentral reviewPerformance scoresCorticosteroid responseResponse assessmentAdverse eventsPractical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients
Ranjan S, Leung D, Ghiaseddin A, Taylor J, Lobbous M, Dhawan A, Budhu J, Coffee E, Melnick K, Chowdhary S, Lu‐Emerson C, Kurz S, Burke J, Lam K, Patel M, Dunbar E, Mohile N, Peters K. Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients. Cancer 2024, 130: 1577-1589. PMID: 38288941, DOI: 10.1002/cncr.35220.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsLow-molecular-weight heparinVenous thromboembolismIntracranial hemorrhageBrain tumorsEfficacy of direct oral anticoagulantsMetastatic brain tumor patientsRisk of intracranial hemorrhageTreatment of venous thromboembolismManagement of venous thromboembolismMetastatic brain tumorsOral anticoagulant useTreat venous thromboembolismOff-label useBrain tumor patientsBrain metastasesOral anticoagulantsAnticoagulant useTumor patientsClinical trialsPatientsClinical guidanceThromboembolismGlioblastomaHeparin
2022
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data From Patients With KRASG12C-Mutant Non-Small Cell Lung CancerPreliminary Activity of Adagrasib in Brain Metastases
Sabari J, Velcheti V, Shimizu K, Strickland M, Heist R, Singh M, Nayyar N, Giobbie-Hurder A, Digumarthy S, Gainor J, Rajan A, Nieblas-Bedolla E, Burns A, Hallin J, Olson P, Christensen J, Kurz S, Brastianos P, Wakimoto H. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data From Patients With KRASG12C-Mutant Non-Small Cell Lung CancerPreliminary Activity of Adagrasib in Brain Metastases. Clinical Cancer Research 2022, 28: 3318-3328. PMID: 35404402, PMCID: PMC9662862, DOI: 10.1158/1078-0432.ccr-22-0383.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerKRAS-mutant non-small cell lung cancerBrain metastasesCerebrospinal fluidAntitumor activityUntreated BMCentral nervous system penetrationDose-dependent pharmacokineticsCell lung cancerKRASG12C inhibitorsPreliminary clinical dataRetrospective database queryCerebrospinal fluid concentrationsPharmacokinetic propertiesExtensive tissue distributionTumor regressionNSCLC xenograftsPreclinical modelsPoor prognosisPreclinical studiesAdagrasibExtended survivalLung cancerClinical dataLong half-life
2021
Functional connectivity of the default mode, dorsal attention and fronto-parietal executive control networks in glial tumor patients
Tordjman M, Madelin G, Gupta P, Cordova C, Kurz S, Orringer D, Golfinos J, Kondziolka D, Ge Y, Wang R, Lazar M, Jain R. Functional connectivity of the default mode, dorsal attention and fronto-parietal executive control networks in glial tumor patients. Journal Of Neuro-Oncology 2021, 152: 347-355. PMID: 33528739, PMCID: PMC8204932, DOI: 10.1007/s11060-021-03706-w.Peer-Reviewed Original ResearchConceptsSeed-based connectivity analysisFronto-parietal networkDefault mode networkHigh-grade gliomasFunctional connectivityFronto-parietal executive control networkGlioma patientsIncreased connectivityFunctional magnetic resonance imagingCorpus callosumDisruption of functional connectivityExecutive control networkPosterior cingulate gyrusPosterior corpus callosumMagnetic resonance imagingResults35 patientsDMN connectivityFrontal cortexMode networkCingulate gyrusDorsal attentionGlial tumorsTumor patientsDecreased connectivityIDH1-R132H
2020
Novel Therapies for Glioblastoma
Liu E, Sulman E, Wen P, Kurz S. Novel Therapies for Glioblastoma. Current Neurology And Neuroscience Reports 2020, 20: 19. PMID: 32445058, DOI: 10.1007/s11910-020-01042-6.Peer-Reviewed Original ResearchConceptsClinical studiesEarly phase clinical studiesNovel radiotherapy approachesSignificant survival benefitMalignant primary brain tumorPhase clinical studiesPersonalized treatment approachesDiverse resistance mechanismsPrimary brain tumorCheckpoint inhibitionRadiotherapy optionsRadiotherapy approachesDose deliveryRadiation modalitiesSurvival benefitBiomarker-drivenTargeted therapyTargeted agentsTreatment optionsNovel therapiesTumor heterogeneityClinical investigationVaccination strategiesBrain tumorsTreatment approaches
2018
PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.
Kurz S, Cabrera L, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee E, Reardon D, Wen P. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology 2018, 91: e1355-e1359. PMID: 30171077, DOI: 10.1212/wnl.0000000000006283.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabBrain NeoplasmsFemaleGliomaHumansMaleMiddle AgedNeoplasm Recurrence, LocalNivolumabProgrammed Cell Death 1 ReceptorRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsRecurrent high-grade gliomaHigh-grade gliomasRetrospective observational studySalvage therapySurvival benefitSingle-institution retrospective observational studyPD-1 blocking antibodiesObservational studyPD-1 inhibitionProgression-free survivalClass IV evidenceConcurrent bevacizumabAntibody nivolumabPD-1Median survivalClinical benefitImproved survivalNivolumabPembrolizumabAdult patientsBevacizumabIV evidenceClinical trialsPatient populationPatients